Wegovy pill launches in the United States at $149 a month for cash payers

Novo Nordisk began selling the Wegovy pill in the United States on Monday, January 5, 2026, making oral semaglutide available at more than 70,000 pharmacies just two weeks after the FDA approved it on December 22, 2025 ^[1][6]. The starting 1.5 mg dose costs $149 a month for people paying cash — about $5 a day — while the highest doses cost $299 ^[6].

What the prices actually are

The self-pay structure has four tiers. The 1.5 mg starter dose is $149 per month. The 4 mg dose is also $149 per month through April 15, 2026, after which it rises to $199 ^[4][6]. The 9 mg and 25 mg doses are $299 per month ^[4][6]. Novo defines one month as a single bottle of 30 tablets ^[3].

One caveat: Novo's own NovoCare price guide already lists the 4 mg dose at $199 per month as the "standard offer," while the launch press release and GoodRx describe the $149 introductory price running through April 15 ^[3][4][6]. The sources are consistent on the 1.5 mg and top-dose prices.

People with commercial insurance may pay as little as $25 a month using the Wegovy savings offer, but that is capped at a maximum savings of $100 per month, and government beneficiaries — including Medicare and Medicaid — are excluded ^[3][6]. Novo says it can change or cancel the program at any time ^[3].

The pill is sold through retail chains including CVS and Costco, through telehealth companies such as Ro, LifeMD and WeightWatchers, through GoodRx, and through Novo's own direct-to-patient channel, NovoCare Pharmacy ^[1][6]. GoodRx says the $149 cash price is available at more than 70,000 retail pharmacies on its platform ^[4].

How it compares with the shot

Injectable Wegovy now runs $349 a month for most doses through Novo's self-pay channel, down from $499 after the company's November pricing deal with the White House, with the 7.2 mg Wegovy HD pen at $399 ^[1][3]. New patients can get the 0.25 mg and 0.5 mg starter pens for $199 a month for the first two fills, an offer running through December 31, 2026 ^[3].

On effectiveness: in the 64-week OASIS 4 trial of 307 adults with obesity or overweight plus a weight-related condition and no diabetes, people taking the 25 mg pill lost an average of 13.6% of body weight versus 2.4% on placebo when all participants were counted regardless of whether they stayed on treatment ^[6]. In the analysis assuming everyone stayed on treatment, the figures were 16.6% versus 2.7% ^[6]. About 76% of pill users lost at least 5% of their body weight, compared with 31% on placebo, from a starting weight of about 235 pounds ^[6]. Common side effects in the trial were similar to those seen with Wegovy injection, including nausea, diarrhea and vomiting ^[6].

The pill is also approved to reduce the risk of major adverse cardiovascular events such as death, heart attack or stroke in adults with overweight or obesity and established heart disease ^[1][6].

Why it matters for patients

For people without obesity drug coverage, a $149 monthly entry price is less than half the $349 self-pay cost of the injection ^[1][3]. That gap is likely to matter most to patients who have been buying compounded semaglutide from telehealth sellers. Novo has said openly that its self-pay and telehealth push is aimed at both insurance gaps and the compounding pharmacies that marketed copies of its drugs during past shortages, and the company frames the launch as a way to help patients get "authentic, FDA-approved medicines and avoid potentially unsafe, unapproved alternatives" ^[1][6].

The pricing is not flat, though. Anyone who titrates up to the 9 mg or 25 mg maintenance dose — the dose studied in OASIS 4 — faces $299 a month, double the starter price ^[4][6]. The $25 copay offer does not apply to people on Medicare or Medicaid ^[3][6].

What happens next

April 15, 2026 is the date the 4 mg introductory cash price is set to end ^[4][6]. Eli Lilly is seeking FDA approval for its own oral obesity drug, orforglipron, which could arrive soon after Novo's ^[1]. It is not yet known how broadly commercial insurers will cover the Wegovy pill.